ANI Pharmaceuticals | ANIP - Operating Expenses


ANI Pharmaceuticals reported $597.21M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 1000K Jun/2026
ANI Pharmaceuticals USD 597.21M 34.91M Jun/2026
Aurora Cannabis CAD 48.04M 81.94M Mar/2026
Canopy Growth CAD 98.72M 11.51M Mar/2026
Eli Lilly USD 10.52B 496M Jun/2026
Emergent BioSolutions USD 555.9M 242.7M Jun/2023
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Knight Therapeutics CAD 126.9M 8.29M Dec/2025
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Omeros USD 59.16M 20.13M Jun/2024
Perrigo USD 290.5M 645.1M Jun/2026
Sun Pharmaceuticals INR 117.43B 648.5M Jun/2026
Teva Pharmaceutical Industries USD 3.92B 691M Jun/2026